Nonalcoholicsteatohepatitis (NASH) – Pipeline Analysis

Date: 2016-09
Pages:112
Price:

““Nonalcoholicsteatohepatitis(NASH)PipelineAnalysis”givescomprehensiveinsightonthevariousdrugsbeingdevelopedforthetreatmentofNASH.Thereportcoversallthedrugsbeingdevelopedinvariousphases(Discovery,Preclinical&Clinicaldevelopment).Thepipelinefocusesonnovelmedicinescoveringsmallmolecules,monoclonalantibodies,RecombinantproteinsandRNA-basedtherapeutics,butexcludesOff-label,symptomreliefdrugs,genericcombinations.ThereportalsocovershottargetsinresearchforNASHtreatmentsanddiseaseprogressionbiomarkers.
ThisreportenablesPharmaceutical/Biotechcompanies,Academicinstitutes,Individualresearchers,Investors,Medicaltechnologycompanies,Serviceprovidersandotherassociatedstakeholderstoidentifyandanalyzetheavailablelicensing/collaborativecommercialopportunitiesintheNonalcoholicsteatohepatitis(NASH)Drugmarket.ThereportalsoprovidesstrategicinsightsonmedicinesthatarelikelytohaveanimpactonfutureNASHtreatmentspace.
NASHisassociatedwithfattyliver,hepaticinflammation,hepatocyteinjuryandfibrogenesisandmayworsenintofibrosisorcirrhosis,liverfailureandrarelyintolivercancer.Currently,therearenoapproveddrugsforNASHbyU.S.FoodandDrugAdministration(FDA)andthereahighunmetclinicalneed.NASH,ifuntreatedcanprogresstoliver-destroyingcirrhosisandpotentiallycancer.MajorityoftheNASHpipelinedrugsarefromspecialisedsmalltomidpharmaceutical&biotechcompanies.AssomeofthecandidatesarenearingkeyR&Dmilestones,thereisahugecompetitionamonglargepharmaceuticalandbiotechcompaniestoacquiretheseassets.Gilead’sacquisitionofPhenexFXRprogram&Boehringer’sacquisitionofNASHclinicalassetfromPharmaxissupportsthistrend.DiagnosisofNASHstillrequireshistologicalconfirmationandthereisagreatdemandforspecificnon-invasivediagnosisfordistinguishingNASHfromotherliverdiseases.Therefore,thereisaneedtodevelopbetterdiagnosticandtherapeuticstrategiesforpatientswithNASH.
ThereisatremendousopportunityforupcomingtherapiesspecifictoNASHsuchasMAbs,RNA-basedtherapies&Recombinantproteins.ThesemodalitiesmayprovideAnti-fibrosis,Anti-inflammatoryandmetabolicbenefits.”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample